KPV vs TB-500

Side-by-side comparison of KPV, TB-500 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery TB-500 Thymosin Beta-4 Synthetic Analogue Recovery
Basics
Molecular type Alpha-MSH C-terminal TripeptideThymic Peptide Analogue
Amino acids 343
Molecular weight 355.4 Da4,921 Da
Half-life Short (hours)Long-acting (days)
Route(s) Subcutaneous, Oral (GI conditions), TopicalSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical …
Research status Research Compound Research Compound
Evidence summary KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been …
Protocol & Dosing
Typical dose 500 mcg–2 mg/day (SC); variable oral dosing5–10 mg per injection
Frequency Once or twice daily2x per week (loading), then weekly
Duration 4–8 weeks4–8 weeks
Timing Any time; pre-meals for GI applicationsNo specific timing requirement
Safety
Common side effects
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
  • Injection site reaction
  • Mild fatigue (transient)
  • Headache
  • Lethargy in first days
Contraindications
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
  • Active cancer (angiogenic activity)
  • Pregnancy
  • Platelet disorders or anticoagulant use
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides BPC-157, LL-37, TB-500 BPC-157, GHK-Cu, Thymosin Alpha-1
Full profile Read full KPV profile → Read full TB-500 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.